since tumor cells may contain both tissue plasminogen activator and a urokinase-like plasminogen activator , the balance between tumor-mediated fibrin formation and fibrinolysis becomes an important issue in assessing antimetastatic treatment protocols .
C0032143
tissue plasminogen activator
C0032144
plasminogen activator